Vimta Labs Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Vimta Labs Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 83.1 times by its yearly operating cash. Higher than 95% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹163Over the last 3 years, every ₹100 of reported profit came with ₹163 of operating cash.
Higher than 77% of Healthcare companies in India.
Self-Funding Ratio
1.2×Over the last 3 years its own operating cash covered its investment spending (capex) 1.2 times.
Lower than 58% of Healthcare companies in India.
Cash Locked Ratio
₹21For every ₹100 of sales, ₹21 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹19 tied up three years earlier.
Less money tied up than 56% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹32Sales grew 29% in 3 years; of every extra ₹100 of sales, ₹32 became extra profit.
Higher than 80% of Healthcare companies in India.
Asset Productivity Ratio
+29% / +55%In 3 years sales changed by +29% while total assets changed by +55%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
83.1×Debt due within a year is covered 83.1 times by its yearly operating cash.
Higher than 95% of Healthcare companies in India.
Cash Cushion Ratio
+3%Cash, after subtracting all debt, equals 3% of its market value (net cash).
Higher than 74% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 62% of Healthcare companies in India.
Tangible Net Worth Ratio
99%Of every ₹100 of net worth, ₹99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 65% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Vimta Labs Limited owes ₹0.19 for every ₹1 it owns. Net profit rose 15% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
26.5Investors pay ₹26.5 for every ₹1 of Vimta Labs Limited's yearly profit, lower than 70% of Healthcare companies in India.
P/B ratio
4.58The share price is 4.58 times Vimta Labs Limited's book value per share, lower than 51% of Healthcare companies in India.
Market cap
₹2,092 CrThe total market value of all of Vimta Labs Limited's shares at today's price (share price × number of shares), smaller than 64% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹457 CrWhat Vimta Labs Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹102.21Net worth divided by the number of shares. The share price of ₹468.00 is 4.6 times this, which is the P/B above.
Return on equity (ROE)
17.2%Vimta Labs Limited earned 17.2% on its shareholders' money over the last year, higher than 68% of Healthcare companies in India.
Owes vs Owns
0.19×Vimta Labs Limited owes ₹0.19 for every ₹1 it owns (low), lower than 84% of Healthcare companies in India.
Dividend yield
0.37%Vimta Labs Limited pays 0.37% of its share price as dividends a year, lower than 51% of dividend-paying Healthcare companies in India.
Revenue growth
+18%Revenue rose 18% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Profit growth
+15%Net profit rose 15% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Profit margin
19.0%Vimta Labs Limited keeps ₹19 of every ₹100 of revenue as net profit.
Cash quality
1.9×Cash from Vimta Labs Limited's business was 1.9× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
208.8×Vimta Labs Limited's operating profit covered its interest costs 208.8 times in the year to Mar 2026.
Cash vs debt
Net cashVimta Labs Limited held ₹64 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Vimta Labs Limited's P/E ratio?
Investors pay ₹26.5 for every ₹1 of Vimta Labs Limited's yearly profit, lower than 70% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Vimta Labs Limited: ₹2,092 Cr ÷ ₹457 Cr (31 Mar 2026) = 4.6.
What is Vimta Labs Limited's return on equity?
Vimta Labs Limited earned 17.2% on its shareholders' money over the last year, higher than 68% of Healthcare companies in India.
How much does Vimta Labs Limited owe compared with what it owns?
Vimta Labs Limited owes ₹0.19 for every ₹1 it owns (low), lower than 84% of Healthcare companies in India.
Does Vimta Labs Limited pay a dividend?
Yes. Vimta Labs Limited pays 0.37% of its share price as dividends a year, lower than 51% of dividend-paying Healthcare companies in India.
Is Vimta Labs Limited's revenue growing?
Revenue rose 18% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.